Gains of the SEC62 gene were found in 3 % of the counted nuclei in normal cases, 4 % of the nuclei in CIN-I cases, 4 % of the nuclei in CIN-II cases, 9 % of nuclei in CIN-III cases and 23 % of nuclei in SCC cases (Fig. 1). The gene discussed is SEC62; the disease is uterine cervix carcinoma in situ.